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Samantha Crossley1, Jenny Reid1, Rachel McLatchie1, Judith Hayton1, Clair Clark1, Margaret MacDougall2
and Peter JD Andrews3*Abstract
Introduction: Research into therapeutic hypothermia following traumatic brain injury has been characterised by
small trials of poor methodological quality, producing variable results. The Cochrane review, published in 2009,
now requires updating. The aim of this systematic review is to assess the effectiveness of the application of
therapeutic hypothermia to reduce death and disability when administered to adult patients who have been
admitted to hospital following traumatic brain injury.
Methods: Two authors extracted data from each trial. Unless stated in the trial report, relative risks and 95%
confidence intervals (CIs) were calculated for each trial. We considered P < 0 · 05 to be statistically significant.
We combined data from all trials to estimate the pooled risk ratio (RR) with 95% confidence intervals for death,
unfavourable outcome, and pneumonia. All statistical analyses were performed using RevMan 5.1 (Cochrane
IMS, Oxford, UK) and Stata (Intercooled Version 12.0, StataCorp LP). Pooled RRs were calculated using the
Mantel-Haenszel estimator. The random effects model of DerSimonian and Laird was used to estimate variances
for the Mantel-Haenszel and inverse variance estimators.
Results: Twenty studies are included in the review, while 18 provided mortality data. When the results of 18
trials that evaluated mortality as one of the outcomes were statistically aggregated, therapeutic hypothermia
was associated with a significant reduction in mortality and a significant reduction in poor outcome. There was
a lack of statistical evidence for an association between use of therapeutic hypothermia and increased onset of
new pneumonia.
Conclusions: In contrast to previous reviews, this systematic review found some evidence to suggest that
therapeutic hypothermia may be of benefit in the treatment of traumatic brain injury. The majority of trials were
of low quality, with unclear allocation concealment. Low quality trials may overestimate the effectiveness of
hypothermia treatment versus standard care. There remains a need for more, high quality, randomised control
trials of therapeutic hypothermia after traumatic brain injury.
PROSPERO Systematic Review Registration Number 2012: CRD42012002449.Introduction
Therapeutic hypothermia has emerged as a potentially
life-saving treatment for the care of the critically ill.
Research in the 1980s using animal models demonstrated
the benefits of cooling to 32 to 34°C [1,2], and it has since
been proposed that there are a number of potential appli-
cations for therapeutic hypothermia [3]. In February 2011,* Correspondence: p.andrews@ed.ac.uk
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Commons Attribution License (http://creativec
reproduction in any medium, provided the orNational Health Service (NHS) National Institute for
Health and Clinical Excellence (NICE) guidelines were
published to support the use of therapeutic hypothermia
for hypoxic ischaemic encephalopathy [4]. Similarly, NICE
guidelines for the use of therapeutic hypothermia in
cardiac arrest have also been published [5]. In the United
States, the American Heart Association recommends
hypothermia as a standard of care for survivors of cardiac
arrest as there is sufficient evidence to support improve-
ments in outcome with its use [6]. Whilst a number of
studies have identified an improvement in outcome with
the application of therapeutic hypothermia followingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thermia is of benefit in traumatic brain injury (TBI)
remains unanswered.
TBI is a leading cause of disability and death, particu-
larly in the young [8]. The application of hypothermia
has been shown to decrease cerebral metabolic rate and
is thought to alter the release of post-trauma excitatory
neurotransmitters [9], reducing and preventing blood-
brain-barrier disruptions during and following cerebral
insults [10]. Laboratory studies have shown positive ben-
efits for prophylactic hypothermia, but clinical trials and
systematic reviews have largely suggested weak evidence
to support the use of therapeutic hypothermia following
TBI [10-16]. Brain Trauma Foundation Guidelines are
most widely followed and do not recommend the use of
therapeutic hypothermia (level III evidence) [11] and
there have also been concerns about possible increased
risk of pneumonia following the induction of therapeutic
hypothermia [9].
A number of reviews have been published into the use
of therapeutic hypothermia following TBI. This systematic
review was designed to identify all randomised controlled
trials (RCTs) that investigate the relationship between TBI
and the application of therapeutic hypothermia in adults.
Aims
Our primary aim was to assess the effect of the applica-
tion of therapeutic hypothermia, when administered to
adult patients who have been admitted to intensive care
following TBI, on the risk of death, unfavourable outcome,
and new pneumonia.
Our secondary aims were to investigate the following
hypotheses: a) duration of cooling greater than 48 hours
improves outcome compared with shorter duration; b)
re-warming patients at a speed of greater than 1°C every
four hours increases the risk of poor outcome; c) patients
who have undergone only modest cooling (35 to 36°C) are
more likely to experience poor outcomes compared with
patients cooled to below 35°C; and d) increased length of
time between the onset of injury and the induction of
cooling increases the risk of poor outcome.
Materials and methods
Search methods for identification of trials
Searches were not restricted by date, language, or publica-
tion status (other than those restrictions imposed by the
databases themselves). Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE, EMBASE, ISI Web
of Science: Science Citation Index Expanded (SCI-EX-
PANDED) and Conference Proceedings Citation Index-
Science (CPCI-S), PubMed, and Zetoc were searched from
the first publicly accessible date of a particular database to
5 January 2012. All electronic database searches were con-
ducted using versions of the MEDLINE search strategy,adapted where necessary for each database. The search
strategy is recorded in the protocol (see Additional file 1).
Other sources
Reference lists of all relevant trials and review articles
were also hand searched and where necessary, authors
were contacted to find information relevant to trials or
conference proceedings.
Ethical approval and consent
This study did not need ethical approval nor was indi-
vidual patient consent needed.
Selection of papers
Methodological criteria
The inclusion criterion was that trials must be RCTs. The
exclusion criteria were trials in which patients had not
been randomised to each treatment arm and/or where
there was no control group managed to normothermia.
The condition or domain being studied was the applica-
tion of therapeutic hypothermia for the treatment of TBI.
We defined TBI as being any acute closed head injury
sustained following head trauma. We defined therapeutic
hypothermia as any intervention carried out with the
intention of reducing core body temperature to below the
physiological norm (36.0°C). Unfavourable outcomes at
the end of the follow-up period included death, persistent
vegetative state or severe disability as defined by the
Glasgow outcome scale (GOS) or equivalent scoring scale
(Ranchos Los Amigos scale).
Participants/population
The inclusion criteria were that patients must be adults
(we defined this as being the legal age for consent in the
country in which the trial was conducted) and patients
enrolled must have had closed head injuries. The exclu-
sion criteria were trials that had been performed entirely
in neonates or children (whom we define as being below
the legal age for consent) and trials containing patients
with open head injuries, such as gunshot wounds.
The output of the searches was exported into Endnote
Web and five individuals sifted the papers in three separ-
ate phases: in sift phase one, the primary output of the
searches was assessed. Papers with titles and abstracts
unrelated to therapeutic hypothermia as a medical inter-
vention or to the general management of TBI were dis-
carded. This was recorded in Endnote web. In sift phase
one, no reason was recorded for exclusion. This was
deemed appropriate because all excluded papers had no
relevance to therapeutic hypothermia or TBI.
In sift phase two, the abstracts of all remaining papers
were assessed against the inclusion and exclusion criteria.
If excluded, a reason was recorded. Reasons for exclusion
in this phase included, but were not limited to: neonatal
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than clinical trials, and therapeutic hypothermia for
reasons other than TBI such as cardiac arrest.
In sift phase three, each remaining paper was reviewed
in full for final inclusion criteria. Reasons for exclusion
were recorded and the eligibility of each paper for inclu-
sion was assessed by at least two authors. Where authors
were uncertain and discrepancies remained, a majority
decision between the authors determined if the trial met
inclusion criteria (papers excluded at sift phase three
can be seen in Additional file 2). The search protocols
and a PRISMA flow diagram (see Additional file 3)
detailing the trial selection process are included in
Additional files 1 and 3.
Data extraction
Each trial was assessed by at least two individuals and
the data extraction was recorded in a data extraction
matrix. The following general information was extracted
from each of the selected trials: trial name and date of
publication, method of intervention, lowest body tempe-
rature obtained, duration of intervention, maximum time
between initial injury and cooling, Glasgow coma scale on
admission, neurological deterioration, speed of re-warming,
whether a sample size calculation was performed and if it
was adhered to, the number of patients, patient outcomes
in the control and treatment groups, and the effect size.
In order to assess the methodological quality of each
trial the authors recorded the allocation concealment
and randomisation technique used, the blinding proced-
ure, reporting of an intention-to-treat analysis, com-
pleteness of follow up, reasons for patient exclusion, and
whether a protocol was published and supplied with
the trial.
In addition, information was extracted on the following
possible confounding factors: whether the control group
was managed to normothermia (considered standard care),
whether the control group was actively rewarmed on
admission (associated with poor outcomes), whether the
treatment arm received barbiturate treatment in addition
to therapeutic hypothermia (associated with poor out-
come), whether there were significant differences be-
tween the treatment and control sample populations,
and whether the standard treatment was clearly outlined.
These data were used to support domain-based assessment
of the risk of bias for each trial (see Additional file 4).
Bias
The methodology described for random sequence gener-
ation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, completeness
of outcome data, and selective reporting were assessed in
our data extraction process using the Cochrane Collabora-
tion’s tool for assessing risk of bias [17].There were a number of trials where randomisation
was stated but the method was unclear (see Additional
file 5). All selected trials were RCTs and met our inclu-
sion criteria. Due to the nature of the intervention,
blinding of trial personnel was not possible and is recog-
nised as a continuing source of weakness amongst trials
of therapeutic hypothermia.
The 20 included trials were assessed according to trial
quality using domain-based assessment of risk of bias,
including potential confounding factors (as described
above) in the design. The assessments for each trial are
included in Additional files 5 and 6. We recognize that
Cochrane discourages the use of scoring systems when
assessing trial quality, and our domain-based assessment
of risk of bias output is simply presence or absence (0 or 1
and similar to Cochrane red or green) of the key domains
used when assessing risk of bias. The total number of
positive domains (maximum 15 domains) was used as a
tool for an exploratory meta-regression analysis.
Data synthesis
Review Manager (RevMan, Cochrane Collaboration, ver-
sion 5.1) and Stata (Intercooled Version 12.0, StataCorp
LP) were used for data sythesis.
Statistical analyses
The relative risk and corresponding 95% CI for death,
poor outcome, and pneumonia were extracted where
they were available or were calculated where this was
not stated in the original trial report. The overall relative
risk, (RRoverall) and corresponding 95% CIs were then
evaluated using the Mantel-Haenszel approach, and the
significance of RRoverall as an effect estimate was assessed
in terms of the null hypothesis RRoverall = 1 using the
z-test. Although the corresponding study hypotheses
were one-sided, two-sided hypothesis tests were assumed,
thus ensuring a more conservative approach to statistical
significance.
Statistical evidence for heterogeneity between trials
was assessed using the Q-test, and the I2 index was used
as an estimate of the extent of between trial variability.
As noted by Huedo-Medina et al. [18], when dealing
with a small sample size, a non-significant result for the
Q-test may result in erroneous selection of the fixed
effects model. In order to mitigate this effect, where a
fixed model was chosen on the basis of a lack of evidence
for heterogeneity, corresponding results for a random
effects analysis (not included here) were generated for
comparative purposes.
Analysis of evidence for bias in selection of trials or
tendency of smaller trials to report stronger effects
Funnel plots and contour-enhanced funnel plots were
used to assess bias, including publication bias, in choice
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report stronger effects. It is possible that smaller trials,
often single-centred, will have the largest treatment
effect. In addition to surveying the above plots, the Begg
and the Egger tests of small-study effects were used as a
further means of testing for the above anomalies.
Sensitivity analysis
Forest plot analyses were performed separately for all
studies and for those at least risk of bias (assessed by
using Cochrane domain-based evaluation). Exploratory
meta-regression analyses were performed on the log-
transformed domain-based evaluation sum-scores for each
of the three principal treatment outcomes in order to test
for an association between trial quality (risk of bias) and
treatment effect (Additional file 7).
Results
Included in the final selection were 20 trials. These trials
enrolled 1,885 patients (see Additional file 6). All trialsFigure 1 Death at final follow-up. (a) In total 18 trials involving 1,839 pa
controlled trials (RCTs) were statistically aggregated, therapeutic hypotherm
(RR) = 1.31, 95% CI = 1.13, 1.52, P = 0.0004). (b) Trials assessed as having low
aggregated, therapeutic hypothermia was associated with a significant redexcept two [19,20] recorded outcomes for death in the
control and treatment groups at final follow-up. All
trials reported the incidence of poor outcome (death,
vegetative state, and long-term disability) in both the
control and treatment groups.
Eight trials did not provide data on the occurrence of
pneumonia during treatment in either the control or
treatment groups [21-28]). For a summary of the charac-
teristics of each trial please refer to Additional file 6.
In analysis of trials that reported death at final follow-
up, 18 trials involving 1,839 patients reported deaths.
When the results of the 18 RCTs were statistically aggre-
gated, therapeutic hypothermia was associated with a sig-
nificant reduction in mortality (relative risk (RR) = 1.31,
95% CI = 1.13 to 1.52, P = 0.0004). As the Q-test showed
no evidence of statistical heterogeneity between the trials
(χ2 = 22.37, P = 0.17, df = 17) a fixed-effects model was
selected. This choice was supported by the low value of the
I2 index (I2 = 24%). A random effects model was generated
and the conclusions are unaffected Figure 1.tients reported deaths. When the results of the 18 randomised
ia was associated with a significant reduction in mortality (relative risk
er risk of bias: when the results of the 14 RCTs were statistically
uction in mortality (RR = 1.62, 95% CI = 1.30, 2.01, P <0.0001).
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of bias, 14 trials involving 918 patients and assessed as
lower risk of bias (domain-based assessment) were included
in this analysis. When the results of the 14 RCTs were
statistically aggregated, therapeutic hypothermia was asso-
ciated with a significant reduction in mortality (RR = 1.62,
95% CI = 1.30, 2.01, P <0.0001). As the Q-test showed a
lack of evidence for statistical heterogeneity between the
trials (χ2 = 9.15, P = 0.76, df = 13) a fixed effects model was
selected. A random effects model was generated and the
conclusions were unaffected (Figure 1b).
In analysis of trials that reported poor outcome at final
follow-up, 20 trials involving 1,885 patients reported
death, vegetative state, and long-term disability. When
the results of 20 RCTs that evaluated poor outcome
were statistically aggregated, therapeutic hypothermia
was associated with a significant reduction in poor out-
come (RR = 1.49, 95% CI = 1.27, 1.74, P <0.00001). As the
Q-test demonstrated that there was statistical evidence of
heterogeneity between the trials (P = 0.004) [12], a random
effects model was used. This choice was supported by the
moderate value for the I2 index (I2 = 51%) (Figure 2).
For poor outcome at final follow-up in trials assessed
as lower risk of bias, 16 trials, involving 964 patients,
and assessed as lower risk of bias (domain-based assess-
ment) were included in this analysis. When the results
of 16 RCTs that evaluated poor outcome were statisti-
cally aggregated, therapeutic hypothermia was associated
with a significant reduction in poor outcome (RR = 1.67,
95% CI = 1.45, 1.92, P <0.00001). As the Q-test showed a
lack of statistical evidence for heterogeneity between the
trials (χ2 = 12.46, P = 0.64, df = 15), a fixed effects model
was selected. A random effects model was generated and
the conclusions were unaffected (Figure 2b).
In analysis of trials that reported the incidence of
pneumonia during the course of treatment: 12 trials, in-
volving 689 patients, reported pneumonia in patients
during the course of treatment. When the data from 12
RCTs were aggregated, therapeutic hypothermia had no
effect on increasing onset of new pneumonia. (RR = 0.81,
95% CI = 0.62, 1.05, P = 0.12). As the Q test demonstrated
that there was evidence of statistical heterogeneity be-
tween the trials (P = 0.04), and the heterogeneity index
suggested a moderate degree of between-study hetero-
geneity (I2 = 46%) a random effects model was used
(Figure 3).
Incidence of pneumonia during the course of treat-
ment; analysis of trials assessed as lower risk of bias.
Nine trials, involving 504 patients, assessed as lower risk
of bias (domain-based assessment) were included in this
analysis. When the data from the nine RCTs that reported
pneumonia were aggregated, therapeutic hypothermia
had no effect on increasing onset of new pneumonia
(RR = 0.87, 95% CI = 0.71, 1.07, P = 0.17). Although,the I2 value of 47% was suggestive of a moderate degree
of between-study heterogeneity, the Q-test revealed a
lack of statistical evidence for this type of heterogeneity
(χ2 = 15.06, P = 0.06, df = 8), and a fixed effects model was
selected. A random effects model was generated and the
conclusions were unaffected (Figure 3b). Standard and
contour-enhanced funnel plots for the three outcome cat-
egories death, poor outcome and pneumonia are included
in Figure 4.
On applying the Begg test (B) and the Egger test (E)
there was a lack of evidence for a small-study effect for
any one of the principal treatment outcomes, death (B:
P = 0.940, E: P = 0 · 353, n = 18), poor outcome (B: P = 0.496
E: P = 0.083, n = 20), and pneumonia (B: P = 0 · 837, E:
P = 0.152, n = 12).
Meta-regression
Using β and the Knapp-Hartung-adjusted regression
coefficient (adjR2) to denote the regression coefficient
and the adjR2, respectively, the results of the meta-regres-
sion analysis with study risk of bias may be summarized
as follows for each of the principal treatment outcomes:
for death, β = −0.612, adjR2 = 0.612, P = 0.065, n = 18;
for poor outcome, β = −0.470, adjR2 = 0.422, P = 0.036,
n = 20; and for pneumonia: β = −1.50, adjR2 = 1.00,
P = 0.018, n = 12.
Discussion
Summary of results
This systematic review shows there is evidence that
therapeutic hypothermia may be beneficial in the treat-
ment of TBI. In the 20 trials included in this systematic
review, treatment with therapeutic hypothermia resulted
in significantly reduced rates of death, vegetative state,
and long-term disability. On removal of the trials with
greatest risk of bias, there was an increase in the RR for
death (1.31 versus 1.62) and an increase in RR for poor
outcome (1.41 to 1.67). Removal of the trials assessed at
greatest risk of bias increased the summary estimate of
effect. However, caution is recommended as the majority
of trials found were of low quality, with unclear allo-
cation concealment. The results indicate that there is a
lack of statistical evidence to indicate that treatment
with hypothermia has an increased risk of pneumonia.
Quality of evidence
Therapeutic hypothermia for TBI has been subject to a
number of trials of varying size and quality, however,
some more recent trials, such as Marion [25] and Clifton
[29], have been of better methodological quality. The
outcome of a domain-based assessment demonstrated
that there are a number of low-quality trials. The impact
of these trial data were assessed in a sensitivity analysis,
by the exclusion of the trials at highest risk of bias from
Figure 2 Poor outcome at final follow-up. (a) In total 20 trials involving 1,885 patients reported death, vegetative state, and long-term
disability. When the results of 20 randomised controlled trials (RCTs) that evaluated poor outcome were statistically aggregated, therapeutic
hypothermia was associated with a significant reduction in poor outcome (relative risk (RR) = 1.49, 95% CI = 1.27, 1.74, P <0.00001). (b) Trials
assessed as lower risk of bias: 16 trials, involving 964 patients, and assessed as lower risk of bias (domain-based assessment) were included in this
analysis. When the results of 16 RCTs that evaluated poor outcome were statistically aggregated, therapeutic hypothermia was associated with a
significant reduction in poor outcome (RR = 1.67, 95% CI = 1.45, 1.92, P <0.00001).
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was reduced, the relative risk remained significant sug-
gesting consistency in outcomes. All selected trials were
randomised control trials, however, even in those that
met the inclusion criteria the majority (see Additional
file 5) had poor explanation of their allocation conceal-
ment and/or randomisation methods were vague.
Limitations and potential bias in the review process
Deviation from protocol
There were insufficient data to fully analyse the second-
ary outcomes; duration of cooling, re-warming rate, and
cooling target temperature. All trials universally stated
that they cooled patients to 35°C or below and all in-
duced cooling within 6 hours of injury.Limitations of the review process
Due to variations in trial protocol there was variation in
the length of time to long-term follow-up, usually
between 3 and 6 months. Due to the limited number of
trials and trial participants the authors were unable to
control for this as a confounding factor.
This systematic review addresses a clear set of primary
outcomes using pre-determined inclusion and exclusion
criteria, and selection methodology as set out in a publicly
available protocol. The pre-published protocol combined
with thorough searching and data analysis has reduced the
selection risk of bias.
The standard funnel plots (Figure 4) for each of the
three main outcomes are designed to display increasing
levels of accuracy in estimation of effect size in moving
Figure 3 Incidence of pneumonia during the course of treatment. (a) In total 12 trials involving 689 patients reported pneumonia in patients
during the course of treatment. When the data from 12 randomised controlled trials (RCTs) were aggregated, therapeutic hypothermia had no
effect on increasing onset of new pneumonia (relative risk (RR) = 0.81, 95% CI = 0.62, 1.05, P = 0.12). (b) Trials assessed as lower risk of bias: 9 trials,
involving 504 patients, assessed as having lower risk of bias (domain-based assessment) were included in this analysis. When the data from the
9 RCTs that reported pneumonia were aggregated, therapeutic hypothermia had no effect on increasing onset of new pneumonia (RR = 0.87,
95% CI = 0.71, 1.07, P = 0.17).
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outcomes, the majority of trials lend themselves to more
accurate estimates, although this is true to a lesser
extent in the case of pneumonia. Typically, publication
bias would be reflected in a relatively high proportion of
trials in the bottom right corner of the plot, due to
smaller trials being withheld where the effect was not in
the desired direction. However, in these cases, the over-
all lack of trials with low accuracy is unsupportive of this
source of bias or indeed, the more plausible idea that
smaller trials tended to produce inflated effect size
estimates in the desired direction. The lack of statistical
significance for all three principal treatment outcomes
following application of the Begg and the Egger tests
was supportive of these findings. Nevertheless, it is
important to bear in mind that in the presence of a
modest number of trials, as in the current review, these
tests have limited statistical power in detecting bias.
Similar conclusions apply in the case of pneumonia,
although here, the loss of trials due to non-events on
both arms of a trial would have further reduced the
statistical power of the corresponding tests of bias.
The contour-enhanced funnel plot serves as a useful
tool in assessing evidence for reported trials being selected
according to level of statistical significance, whetherthrough publication bias or through bias arising during
the conduct of this study. Only in the case of poor
outcome does there appear to be a clustering of this
particular sort in the data (Figure 4 4.2b) Although this
clustering is around favourable outcomes and in proximity
to the region of statistical significance, the absence of this
phenomenon for death alone is noteworthy (compare to
Figure 4 4.1b). In particular, it is possible that the merging
of multiple outcomes in defining poor outcome and the
corresponding increase in statistical power afford legi-
timate reasons for the particular clustering effect for poor
outcome. To assess the accuracy of this hypothesis, how-
ever, larger RCTs are necessary to support consideration
of relative risks for more specific levels of severity of
outcome.
The exploratory meta-regression analyses reveal a
negative relationship between effect size estimate and
study risk of bias. This is true for each of the principal
outcomes death, poor outcome, and pneumonia. These
results also reveal that this relationship was statistically
significant in the case of poor outcome and pneumonia
and fairly close to achieving statistical significance in the
case of death. Thus, there is good reason to regard the
possible beneficial effects of therapeutic hypothermia in
preventing death or poor outcome more tentatively. Such
Figure 4 Funnel plots to investigate evidence of bias. (4.1) Death. (a) Standard funnel plot. (b) Contour-enhanced funnel plot. (4.2) Poor
outcome. (a) Standard funnel plot. (b) Contour-enhanced funnel plot. (4.3) Pneumonia; RR, relative risk (equivalently, risk ratio). (a) Standard
funnel plot. (b) Contour-enhanced funnel plot.
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vide more reliable evidence in identifying the potential
benefits and harms arising from therapeutic hypothermia
in adults following TBI.
The above findings from the assessment of study bias
can inform this process. Precisely, if, as would seem to
be the case for the studies considered here, sample size
does not have a dominant role to play in explaining
possible relationships between effect size estimate and
study quality, and other components of the domain-based
assessment also need to be taken carefully into consider-
ation during the trial design process.
Similarities and differences to other reviews
This systematic review differs from previous reviews as
analysis of the 20 studies included in the final selection
indicates a statistically significant benefit in the use of
therapeutic hypothermia for TBI. The strength of our
meta-analysis is based on the fact that we have used
several methods to reduce bias (comprehensive literature
search, duplicate data abstraction, specific criteria for
searching and analysis, risk of bias assessment), have
focused on clinically important primary outcomes, and
crucially, have excluded trials that include pediatric
patients. The previous Cochrane reviews included trials
with paediatric patients, however as noted by Adelson et al.
[12] TBI in the paediatric population involves ‘unique
mechanisms, pathophysiologic sequalae, and resultant
poor outcomesʼ, potentially causing an altered response to
the use of therapeutic hypothermia. Additionally, outcome
measures in paediatric patients require careful consider-
ation and are different from those used in adult assess-
ment. Previous reviews have included trials where the
functional recovery was assessed by another scale or
system than GOS. This review shows results of trials
with specific and standardised neurological outcome
assessment.
All international trials were included in this review
providing they met the selection criteria, whereas other
reviews have chosen not to include these trials. Where
there was no justifiable reason to remove trials from
regions that have been criticized for equivocal method-
ology and methodology reporting (for example, China),
the trials were included. Neither the meta-regression nor
the funnel plots showed that this resulted in trial
selection bias. The authors recognise that a thorough
assessment of trial quality (particularly, risk of bias) as
an important factor and therefore utilised a Cochrane
domain-based evaluation tool, that was expanded to
include other sources of bias that are relevant only in
certain circumstances. In particular hypothermia trials
can be subject to bias in the way the control group is
managed (see Additional files 5 and 6). A table detailing
the differences between this systematic review and theprevious Cochrane review [9,15] can be found in
Additional file 8.
Ongoing trials of therapeutic hypothermia for traumatic
brain injury
There are three ongoing or not yet reported trials. This
review identified 20 trials of predetermined quality that
recruited only adult patients. All 20 trials studied early
hypothermia (within 6 hours of injury) to determine if
there was evidence for prophylactic therapeutic hypo-
thermia providing neuroprotection after TBI. There is
one ongoing trial, the Prophylactic Hypothermia Trial
to Lessen Traumatic Brain Injury (POLAR)-RCT [30]
(interim analysis in 2013 and due to report in 2014)
and one trial that has not yet been reported, Therapeutic
Hypothermia for Severe Traumatic Brain Injury in Japan
(BIHYPO) [31] (closed due to futility of recruitment),
that both further evaluate prophylactic therapeutic
hypothermia after TBI. Data from BIHYPO were kindly
provided by the investigator, Professor Maekawa in ab-
stract form only and included in this review.
Commonly, therapeutic hypothermia after TBI is used
to reduce raised intracranial pressure (ICP). As yet, no
study has investigated if titrated therapeutic hypothermia
for raised ICP after TBI reduces death and disability.
The Eurotherm3235Trial [32] (due to report in 2017) is
a pragmatic trial that is funded by The National Institute
for Health Research Health Technology Assessment
(NIHR HTA) Programme and will contribute to address-
ing this important hypothesis.
Conclusions
This systematic review shows that there may be reduced
rates of death and long-term disability among adult
patients who receive therapeutic hypothermia treatment
following TBI. The results indicate that there is a lack of
evidence to suggest that patients treated with thera-
peutic hypothermia have an increased risk of pneumo-
nia. The authors recognise that therapeutic hypothermia
trials pose challenges in recruitment. However there is a
need for more high-quality, multicentre, RCTs. Additional
work is needed to provide more robust evidence for
the benefits and harms before therapeutic hypothermia
becomes a widely adopted treatment strategy following
TBI. However, the authors believe that therapeutic hypo-
thermia must not be disregarded in the treatment of TBI
in adults.
Key messages
 This systematic review shows there is
evidence that therapeutic hypothermia
may be beneficial in the treatment of TBI.
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http://ccforum.com/content/18/2/R75 The results indicate that there is a lack of statistical
evidence to indicate that treatment with
hypothermia has an increased risk of pneumonia
when used after TBI.
 The majority of trials were of low quality, with
unclear allocation concealment.
 The exploratory meta-regression analyses reveal a
negative relationship between effect size estimate
and study risk of bias for each of the principal
outcomes death, poor outcome, and pneumonia.
 There remains a need for more, high quality,
RCTs of therapeutic hypothermia after TBI.
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Additional file 8: Differences between this systematic review and
the most recent Cochrane review.
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